ticagrelor + apixaban

Ticagrelor + apixaban is a combination of two oral small molecule drugs used for antithrombotic therapy, particularly in patients with cardiovascular diseases who require both anticoagulant and antiplatelet effects. Ticagrelor is a reversible P2Y12 receptor antagonist that inhibits ADP-induced platelet activation and aggregation, thereby reducing the risk of thrombotic events such as myocardial infarction and stroke. Apixaban is a direct, selective inhibitor of coagulation factor Xa, which prevents thrombin generation and clot formation. This combination may be considered in specific clinical scenarios such as acute coronary syndrome with atrial fibrillation or other situations where both platelet inhibition and anticoagulation are indicated. However, the use of this dual therapy increases bleeding risk compared to monotherapy or less intensive regimens[1][2][3][4]. The combination does not have an approved fixed-dose product; it refers to concurrent administration of the two agents.